Steven Zeldenrust
Overview
Explore the profile of Steven Zeldenrust including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Muchtar E, Dispenzieri A, Leung N, Lacy M, Buadi F, Dingli D, et al.
Leukemia
. 2018 Mar;
32(10):2240-2249.
PMID: 29581546
Organ recovery following anti-plasma cell therapy is associated with improved outcome in patients with AL amyloidosis. Current organ response criteria do not consider the depth of response. Newly diagnosed AL...
12.
Muchtar E, Dispenzieri A, Lacy M, Buadi F, Kapoor P, Hayman S, et al.
Br J Haematol
. 2017 Jul;
178(6):888-895.
PMID: 28699650
The significance of serum lactate dehydrogenase (LDH) in light chain (AL) amyloidosis has not been previously explored. We studied 1019 newly diagnosed patients and correlated the elevation of LDH above...
13.
Muchtar E, Dispenzieri A, Kumar S, Buadi F, Lacy M, Zeldenrust S, et al.
Amyloid
. 2017 Apr;
24(sup1):40-41.
PMID: 28434371
No abstract available.
14.
Muchtar E, Dispenzieri A, Kumar S, Buadi F, Lacy M, Zeldenrust S, et al.
Amyloid
. 2017 Apr;
24(sup1):44-45.
PMID: 28434304
No abstract available.
15.
Muchtar E, Dispenzieri A, Lacy M, Buadi F, Kapoor P, Hayman S, et al.
Ann Med
. 2017 Mar;
49(7):545-551.
PMID: 28271734
Introduction: The diagnosis of amyloidosis requires histological confirmation of Congo-red (CR) deposits. The tissue source is preferably fat aspiration and/or bone marrow (BM) biopsy, but at times organ biopsy is...
16.
Muchtar E, Gertz M, Kumar S, Lacy M, Dingli D, Buadi F, et al.
Blood
. 2017 Jan;
129(15):2111-2119.
PMID: 28126928
In light of major advances in immunoglobulin light chain (AL) amyloidosis, we evaluated the trends in presentation, management, and outcome among 1551 newly diagnosed AL amyloidosis patients seen in our...
17.
Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi F, Lacy M, et al.
Blood
. 2016 Oct;
129(1):82-87.
PMID: 27729322
Multiparametric flow cytometry (MFC) in amyloid light-chain (AL) amyloidosis has not been widely adopted and, consequently, there is little information on its clinical relevance. We studied 173 patients with AL...
18.
Muchtar E, Derudas D, Mauermann M, Liewluck T, Dispenzieri A, Kumar S, et al.
Mayo Clin Proc
. 2016 Oct;
91(10):1354-1361.
PMID: 27712634
Objective: To characterize the natural history of immunoglobulin light chain amyloidosis-associated myopathy and to provide guidelines for recognition. Patients And Methods: Fifty-one patients with systemic immunoglobulin light chain amyloidosis and...
19.
Muchtar E, Dispenzieri A, Kumar S, Dingli D, Lacy M, Buadi F, et al.
Haematologica
. 2016 Aug;
101(9):1102-9.
PMID: 27479823
Clinical tools to guide in the appropriate treatment selection in immunoglobulin light chain (AL) amyloidosis are not well developed. We evaluated the response and outcome for various regimens at first-line...
20.
Hwa Y, Kumar S, Gertz M, Lacy M, Buadi F, Kourelis T, et al.
Am J Hematol
. 2016 Jun;
91(10):984-8.
PMID: 27341539
There is no consensus on whether patients with immunoglobulin light chain amyloidosis (AL) should receive induction therapy prior to an autologous stem cell transplant (ASCT). This study investigated the relationships...